Oncology

Beyond logistics, new AI-powered systems are redefining trust and efficiency in drug development. See how one company is setting a new human-centered standard.

A new alliance between Guardant Health and Trial Library uses AI and massive datasets to dismantle barriers, connecting more patients to vital cancer research.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Promising data for NuCana's NUC-7738 offers hope for tough-to-treat melanoma, but the biotech's financial health presents a critical hurdle.

Impressive new trial data for MDNA11 could disrupt the multi-billion dollar immunotherapy market, offering real hope where standard treatments now fail.

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

A French cancer institute is the first in Europe to deploy a new radiotherapy system that promises not just better accuracy, but a more humane patient journey.

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.